<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000299584">
  <TermName>semaxanib</TermName>
  <TermPronunciation>(seh-MAK-suh-nib)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance that has been studied in the treatment of cancer. It belongs to the families of drugs called angiogenesis inhibitors and tyrosine kinase inhibitors. Also called SU5416.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000710222" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;semaxanib&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000710221" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;semaxanib&quot;" language="es" id="_4"/>
  <SpanishTermName>semaxanib</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento del cáncer. Es un tipo de inhibidor de la angiogénesis  y de inhibidor de tirosina–cinasas. También se llama SU5416.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2003-03-24</DateFirstPublished>
  <DateLastModified>2005-05-26</DateLastModified>
</GlossaryTerm>
